Monopar Therapeutics Inc
NASDAQ:MNPR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Kukje Pharma Co Ltd
KRX:002720
|
KR |
Monopar Therapeutics Inc
Other Items
Monopar Therapeutics Inc
Other Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Monopar Therapeutics Inc
NASDAQ:MNPR
|
Other Items
-$63.5m
|
CAGR 3-Years
-135%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Other Items
-$5.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
32%
|
CAGR 10-Years
8%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Other Items
-$4.2B
|
CAGR 3-Years
-35%
|
CAGR 5-Years
21%
|
CAGR 10-Years
10%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Other Items
-$85m
|
CAGR 3-Years
74%
|
CAGR 5-Years
55%
|
CAGR 10-Years
33%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Other Items
-$507.8m
|
CAGR 3-Years
-63%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Other Items
$584.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
Monopar Therapeutics Inc
Glance View
Monopar Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. The company is headquartered in Wilmette, Illinois and currently employs 9 full-time employees. The company went IPO on 2019-12-19. The firm is primarily focused on developing therapeutics designed for cancer patients. Its product pipeline includes Validive, camsirubicin, MNPR-101, and MNPR-202. The Validive is a first-in-class mucoadhesive buccal tablet for the prevention of radiation induced severe oral mucositis (SOM) in oropharyngeal cancer patients. Its camsirubicin is a clinical stage topoisomerase II-alpha selective novel analog of doxorubicin engineered specifically to retain anticancer activity while minimizing toxic effects on the heart. Its MNPR-101 is a humanized monoclonal antibody designed to bind a specific cell surface receptor found on cancer cells, the urokinase plasminogen activator receptor (uPAR), and to interrupt several pathways required for tumor growth and progression. The MNPR-202 is an early stage camsirubicin analog for various cancers.
See Also
What is Monopar Therapeutics Inc's Other Items?
Other Items
-63.5m
USD
Based on the financial report for Dec 31, 2025, Monopar Therapeutics Inc's Other Items amounts to -63.5m USD.
What is Monopar Therapeutics Inc's Other Items growth rate?
Other Items CAGR 3Y
-135%
Over the last year, the Other Items growth was -343%. The average annual Other Items growth rates for Monopar Therapeutics Inc have been -135% over the past three years .
